相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri et al.
Journal of the National Comprehensive Cancer Network (2017)
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
Aurore Blesius et al.
BMC CANCER (2011)
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
Axel Le Cesne et al.
LANCET ONCOLOGY (2010)
A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis
John C. McAuliffe et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
Axel Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST): Early Results of RTOG 0132/ACRIN 6665
Burton L. Eisenberg et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Molecular pathobiology of gastrointestinal stromal sarcomas
Christopher L. Corless et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
Ronald P. DeMatteo et al.
CANCER (2008)
Risk stratification of patients diagnosed with gastrointestinal stromal tumor
Heikki Joensuu
HUMAN PATHOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Surgically managed gastrointestinal stromal tumors: A comparative and prognostic analysis
Imran Hassan et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib
Robert H. I. Andtbacka et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era
S. Bonvalot et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
Chandrajit P. Raut et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
P Rutkowski et al.
JOURNAL OF SURGICAL ONCOLOGY (2006)
Gastrointestinal stromal tumours:: Consensus statement on diagnosis and treatment
ME Blackstein et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2006)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
S Singer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diagnosis of gastrointestinal stromal tumors: A consensus approach
CDM Fletcher et al.
HUMAN PATHOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
